Dyadic International, Inc. (DYAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.1000

-0.0200

(-0.94%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	2.1200
Open	2.1300
Bid	2.0900 x 800
Ask	2.7000 x 2200
Day's Range	2.0700 - 2.2893
52 Week Range	1.7400 - 6.8900
Volume	49,897
Avg. Volume	63,525

Market Cap	59.355M
Beta (5Y Monthly)	0.45
PE Ratio (TTM)	N/A
EPS (TTM)	-0.4380
Earnings Date	Aug 10, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DYAI

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Dyadic International, Inc.
Technical Assessment: Bearish in the Intermediate-TermVolatility in West Texas Intermediate (WTI) crude oil has started to shrink a bit, with the recent range between the high $90s and $110 and with WTI currently sitting at $105/barrel. After going parabolic in March and reaching $130, crude oil pulled back to $93.50, rallied back to $116.65, and fell to an intraday low of $93 on April 11 before rallying back above $107. It is still possible that WTI is tracing out symmetrical triangle, although the past breakout attempt in early May failed.
Rating
Fair Value
Economic Moat
10 days agoArgus Research

All

GlobeNewswire
Dyadic to Present at H.C. Wainwright Global Investment Conference
JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the 2022 H.C. Wainwright Global Investment Conferenc
- Identity and Access Management & Cybersecurity Provider BIO-key to Participate in H.C. Wainwright Global Investment Conference, CEO Presentation Available Starting Tue., May 24
  GlobeNewswire
- Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
  GlobeNewswire
Zacks Small Cap Research
DYAI: First Quarter 2022 Operational & Financial Results
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released 2021 operational and financial results in a press release on May 12, 2022, subsequently filing its 10-Q with the SEC and hosting a conference call with investors. Highlights for the first quarter and to-date include: ➢ Exclusive animal health license agreement with Phibro -
GlobeNewswire
Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments
New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical trial application (CTA) to South African Health Products Regulatory Authority (SAHPRA) to support clinical safety of C1 produced proteinsC1 produced COVID-19 monoclonal antibody (mAb) demonstrated broad neutralization and protection agains